Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2020 18:53 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at the ESMO Virtual Congress and Two Investor Conferences in September

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
July 30, 2020 07:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors

Webcast/conference call scheduled today, July 30th at 8:00 a.m. EDT Three of five patients achieved separate RECIST responses after GEN-009 administration GEN-009 elicited antigen-specific CD4+ and...
July 23, 2020 07:00 ET | Source: Genocea Biosciences, Inc.

Genocea Provides Second Quarter 2020 Corporate Update

Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDTFiled IND application for GEN-011 and is working with the FDA to provide additional informationPrivate Placement with Leading Life...
July 22, 2020 09:02 ET | Source: Genocea Biosciences, Inc.

Genocea Announces Private Placement Financing of Up to $80 Million

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has...
July 20, 2020 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Biosciences Provides Clinical Update

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced...
July 16, 2020 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second...
June 22, 2020 09:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Present Data that Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology at AACR Virtual Annual Meeting II

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy Inhibigens alter the tumor microenvironment and drive tumor hyperprogression Inhibigens abolish both global and...
June 15, 2020 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Files IND Application for GEN-011, a T cell Therapy Designed to Improve on Current Limitations of TIL Therapy

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the...
May 29, 2020 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A at Virtual ASCO 2020

Data show immune responses occur rapidly after only two vaccinations and can be sustained for more than one year Part B is exploring the vaccine's ability to reduce tumor size beyond the...
May 19, 2020 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has...